Cincor Pharma, Inc.

CINCCIK 0001868734 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K filed Mar 22, 2022. Sentiment + YoY language diff vs prior year. Read sections →

Signal:No prior 10-KFull-doc fallback

Full filing:tone -0.0162

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Cincor Pharma, Inc.

Name	Roles	Filings
Sofinnova Venture Partners X, L.P.	10% Owner	2
5am Opportunities II (Gp), LLC	10% Owner	1
5am Opportunities II, L.P.	10% Owner	1
Cinrx Pharma, LLC	10% Owner	1
Coelho Mary Theresa	Officer	1

Showing 16-20 of 40

Per pagePrevPage 4 of 8Next

All filings

31 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Feb 24, 2023	Pearce Catherine Chief Operating Officer	UTender	140,149	-	-
Feb 24, 2023	Lee June Director	Holdings only	-	-	-
Feb 24, 2023	Kalb Michael Wayne EVP & Chief Financial Officer	DDisposition	202,437	-	-
Feb 24, 2023	Ignelzi Troy A. Director	Holdings only	-	-	-
Feb 24, 2023	Allison David D. Director	Holdings only	-	-	-

Showing 6-10 of 31

Per pagePrevPage 2 of 7Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value